Switch theme
Sign up to access all valuation multiples
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.
1998
158
LTM Revenue $86.9M
LTM EBITDA $19.9M
$830M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xvivo Perfusion has a last 12-month revenue of $86.9M and a last 12-month EBITDA of $19.9M.
In the most recent fiscal year, Xvivo Perfusion achieved revenue of $81.7M and an EBITDA of $28.7M.
Xvivo Perfusion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xvivo Perfusion valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $59.3M | $81.7M | XXX | XXX | XXX |
| Gross Profit | $29.5M | $44.2M | XXX | XXX | XXX |
| Gross Margin | 50% | 54% | XXX | XXX | XXX |
| EBITDA | $17.1M | $28.7M | XXX | XXX | XXX |
| EBITDA Margin | 29% | 35% | XXX | XXX | XXX |
| Net Profit | $1.8M | $9.1M | XXX | XXX | XXX |
| Net Margin | 3% | 11% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Xvivo Perfusion's stock price is SEK 278 (or $28).
Xvivo Perfusion has current market cap of SEK 8.7B (or $868M), and EV of SEK 8.4B (or $830M).
See Xvivo Perfusion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $830M | $868M | XXX | XXX | XXX | XXX | $0.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Xvivo Perfusion has market cap of $868M and EV of $830M.
Xvivo Perfusion's trades at 9.6x LTM EV/Revenue multiple, and 41.7x LTM EBITDA.
Analysts estimate Xvivo Perfusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Xvivo Perfusion and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $830M | XXX | XXX | XXX |
| EV/Revenue | 10.2x | XXX | XXX | XXX |
| EV/EBITDA | 28.9x | XXX | XXX | XXX |
| P/E | 50.8x | XXX | XXX | XXX |
| P/E/Growth | 2.7x | XXX | XXX | XXX |
| EV/FCF | -102.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpXvivo Perfusion's NTM/LTM revenue growth is 25%
Xvivo Perfusion's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Xvivo Perfusion's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Xvivo Perfusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Xvivo Perfusion and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 38% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 68% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 60% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 64% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xvivo Perfusion acquired XXX companies to date.
Last acquisition by Xvivo Perfusion was XXXXXXXX, XXXXX XXXXX XXXXXX . Xvivo Perfusion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Xvivo Perfusion founded? | Xvivo Perfusion was founded in 1998. |
| Where is Xvivo Perfusion headquartered? | Xvivo Perfusion is headquartered in Sweden. |
| How many employees does Xvivo Perfusion have? | As of today, Xvivo Perfusion has 158 employees. |
| Who is the CEO of Xvivo Perfusion? | Xvivo Perfusion's CEO is Mr. Christoffer Rosenblad. |
| Is Xvivo Perfusion publicy listed? | Yes, Xvivo Perfusion is a public company listed on STO. |
| What is the stock symbol of Xvivo Perfusion? | Xvivo Perfusion trades under XVIVO ticker. |
| When did Xvivo Perfusion go public? | Xvivo Perfusion went public in 2012. |
| Who are competitors of Xvivo Perfusion? | Similar companies to Xvivo Perfusion include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Xvivo Perfusion? | Xvivo Perfusion's current market cap is $868M |
| What is the current revenue of Xvivo Perfusion? | Xvivo Perfusion's last 12-month revenue is $86.9M. |
| What is the current EBITDA of Xvivo Perfusion? | Xvivo Perfusion's last 12-month EBITDA is $19.9M. |
| What is the current EV/Revenue multiple of Xvivo Perfusion? | Current revenue multiple of Xvivo Perfusion is 9.6x. |
| What is the current EV/EBITDA multiple of Xvivo Perfusion? | Current EBITDA multiple of Xvivo Perfusion is 41.7x. |
| What is the current revenue growth of Xvivo Perfusion? | Xvivo Perfusion revenue growth between 2023 and 2024 was 38%. |
| Is Xvivo Perfusion profitable? | Yes, Xvivo Perfusion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
